首页|Chengdu University Reports Findings in Inflammatory Bowel Disease (Therapeutic e ffects of epigallocatechin-3-gallate for inflammatory bowel disease: A preclinic al meta-analysis)
Chengdu University Reports Findings in Inflammatory Bowel Disease (Therapeutic e ffects of epigallocatechin-3-gallate for inflammatory bowel disease: A preclinic al meta-analysis)
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Digestive System Disea ses and Conditions - Inflammatory Bowel Disease is the subject of a report. Acco rding to news originating from Chengdu,People's Republic of China,by NewsRx co rrespondents,research stated,"Epigallocatechin-3-gallate (EGCG),the primary a ctive compound in green tea,is recognized for its significant anti-inflammatory properties and potential pharmacological effects on inflammatory bowel disease (IBD). However,comprehensive preclinical evidence supporting the use of EGCG in treating IBD is currently insufficient." Our news journalists obtained a quote from the research from Chengdu University,"To evaluate the efficacy of EGCG in animal models of IBD and explore potential underlying mechanisms,serving as a groundwork for future clinical investigatio ns. A systematic review of pertinent preclinical studies published until Septemb er 1,2023,in databases such as PubMed,Embase,Web of Science,and Cochrane Li brary was conducted,adhering to stringent quality criteria. The potential mecha nisms via which EGCG may address IBD were summarized. STATA v16.0 was used to pe rform a meta-analysis to assess IBD pathology,inflammation,and indicators of o xidative stress. Additionally,dose-response analysis and machine learning model s were utilized to evaluate the dose-effect relationship and determine the optim al dosage of EGCG for IBD treatment. The analysis included 19 studies involving 309 animals. The findings suggest that EGCG can ameliorate IBD-related pathology in animals,with a reduction in inflammatory and oxidative stress indicators. T hese effects were observed through significant changes in histological scores,D isease Activity Index,Colitis Macroscopic Damage Index and colon length; a decr ease in markers such as interleukin (IL)-1b,IL-6 and interferon-g; and alterati ons in malondialdehyde,superoxide dismutase,glutathione,and catalase levels. Subgroup analysis indicated that the oral administration route of EGCG exhibited superior efficacy over other administration routes. Dose-response analysis and machine learning outcomes highlighted an optimal EGCG dosage range of 32-62 mg/k g/day,with an intervention duration of 4.8-13.6 days."
ChengduPeople's Republic of ChinaAsi aBowel Diseases and ConditionsCyborgsDigestive System Diseases and Conditi onsDrugs and TherapiesEmerging TechnologiesGastroenteritisGastrointestin al Diseases and ConditionsHealth and MedicineInflammationInflammatory Bowe l DiseaseMachine Learning
NETL
NSTL
